Arvinas, Inc. (ARVN)
NASDAQ: ARVN · Real-Time Price · USD
13.08
+0.19 (1.47%)
Jan 26, 2026, 11:41 AM EST - Market open
Arvinas Employees
Arvinas had 430 employees as of December 31, 2024. The number of employees decreased by 15 or -3.37% compared to the previous year.
Employees
430
Change (1Y)
-15
Growth (1Y)
-3.37%
Revenue / Employee
$726,279
Profits / Employee
-$136,047
Market Cap
840.05M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 430 | -15 | -3.37% |
| Dec 31, 2023 | 445 | 30 | 7.23% |
| Dec 31, 2022 | 415 | 135 | 48.21% |
| Dec 31, 2021 | 280 | 101 | 56.42% |
| Dec 31, 2020 | 179 | 46 | 34.59% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 837 |
| Valneva SE | 713 |
| KalVista Pharmaceuticals | 270 |
| Geron | 229 |
| Prime Medicine | 214 |
| Omeros | 202 |
| enGene Holdings | 82 |
| Arbutus Biopharma | 44 |
ARVN News
- 7 weeks ago - Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition - GlobeNewsWire
- 2 months ago - Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 2 months ago - Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS) - GlobeNewsWire
- 2 months ago - Arvinas, Inc. (ARVN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire
- 3 months ago - Arvinas to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025 - GlobeNewsWire